PCSA Share Price | Processa Pharmaceuticals, Inc. Stock Analysis & Recommendation

Q: What does Processa Pharmaceuticals, Inc. do?

Overview: Processa Pharmaceuticals, Inc. is a pharmaceutical company focused on developing drug products aimed at improving the survival and quality of life for patients with unmet medical needs, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) Market-cap: USD 3.09 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.81 Return on Equity: -339.08% Price to Book: 0.88Contact Details: Address: 7380 Coca Cola Dr Ste 106, HANOVER MD: 21076-1789 Tel: 1 443 7763133 Fax: 1 443 2884420

Q: Is Processa Pharmaceuticals, Inc. technically bullish or bearish?

As of 23 June 2025, the technical trend for Processa Pharmaceuticals, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by daily moving averages and Dow Theory both indicating bearishness. Weekly and monthly MACD readings are mildly bullish, but the overall trend remains negative. The RSI shows a bullish signal on the monthly timeframe, while Bollinger Bands indicate a mildly bearish stance. The stock has significantly underperformed against the S&P 500, with a year-to-date return of -76.53% compared to the S&P 500's 12.22%.

Results Declared: Processa Pharmaceuticals, Inc. has declared results on 18 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

6.67 k

Shareholding (Dec 2025)

FII

0.36%

Held by 3 FIIs

DII

98.4%

Held by 1 DIIs

Promoter

0.00%

How big is Processa Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Processa Pharmaceuticals, Inc. has a market capitalization of 3.09 million and reported net sales of 0.00 million, with a net profit of -11.95 million over the last four quarters. The balance sheet shows shareholder's funds of 1.70 million and total assets of 3.23 million.

View full answer

What does Processa Pharmaceuticals, Inc. do?

22-Jun-2025

Processa Pharmaceuticals, Inc. is a micro-cap pharmaceutical company focused on developing drug products to improve survival and quality of life for patients with unmet medical needs. As of March 2025, it reported a net profit loss of $3 million and has a market cap of $3.09 million.

View full answer

Who are in the management team of Processa Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Processa Pharmaceuticals, Inc. includes Dr. David Young as Chairman, CEO, and Founder, along with Directors Dr. Khalid Islam, Ms. Geraldine Pannu, Mr. Virgil Thompson, and Mr. Justin Yorke.

View full answer

Is Processa Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of June 23, 2025, Processa Pharmaceuticals, Inc. is in a mildly bearish trend, with daily indicators suggesting bearishness despite some bullish signals on longer timeframes, and it has underperformed the S&P 500 with a year-to-date return of -76.53%.

View full answer

Compare Processa Pharmaceuticals, Inc. with Similar Stocks

Aileron Therapeutics, Inc.Xenetic Biosciences, Inc.Titan Pharmaceuticals, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 7 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.08

Return on Equity

-221.71%

Price to Book

1.21

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-3 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-30.06%

6 Months

-56.14%

1 Year

-78.14%

2 Years

-95.8%

3 Years

-99.03%

4 Years

-99.86%

5 Years

-99.96%

Processa Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-178.62%

EBIT to Interest (avg)

-14.47

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.81

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

1.67%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.21

EV to EBIT

-0.06

EV to EBITDA

-0.06

EV to Capital Employed

-0.78

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-221.71%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 2 Schemes (1.24%)

Foreign Institutions

Held by 3 Foreign Institutions (0.36%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -25.93% vs -12.50% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.70",
          "val2": "-2.70",
          "chgp": "-37.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.40",
          "val2": "-2.70",
          "chgp": "-25.93%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -14.29% vs -7.21% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.00",
          "val2": "-12.10",
          "chgp": "-15.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.60",
          "val2": "-11.90",
          "chgp": "-14.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-3.70

-2.70

-37.04%

Interest

0.00

Exceptional Items

0.30

0.00

Consolidate Net Profit

-3.40

-2.70

-25.93%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -25.93% vs -12.50% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-14.00

-12.10

-15.70%

Interest

0.00

Exceptional Items

0.30

0.00

Consolidate Net Profit

-13.60

-11.90

-14.29%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -14.29% vs -7.21% in Dec 2024

All Annual Results

Company CV

About Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

Processa Pharmaceuticals, Inc., formerly Heatwurx, Inc., is a pharmaceutical company. The Company is focused on the development of drug products that are intended to improve the survival and/or quality of life for patients who have unmet medical need. The Company’s product portfolio includes 499. It is developing 499 for the treatment of Necrobiosis Lipoidica. It is also developing 499 for the treatment of effects related to head and neck cancer.

Company Coordinates

Company Details

7380 Coca Cola Dr Ste 106 , HANOVER MD : 21076-1789

Tel: 1 443 7763133

Registrar Details